Extended-release trazodone in the treatment of major depressive disorder

被引：0

作者：

Karamustafalioglu, Oguz ^{[1
]}

Dilbaz, Nesrin ^{[2
]}

Caykoylu, Ali ^{[3
]}

Alkin, Tunc ^{[4
]}

Gonul, Ali Saffet ^{[5
]}

Atmaca, Murad ^{[6
]}

机构：

[1] Adli Tip Kurumu, Istanbul, Turkey

[2] Uskudar Univ, ITBF Psikol Bolumu, Istanbul, Turkey

[3] Ankara Yildirim Beyazit Univ, Psikiyatri & Davranissal Norobilim Uygulama & Ara, Ankara, Turkey

[4] Dokuz Eylul Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey

[5] Ege Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey

[6] Firat Univ, Tip Fak, Psikiyatri ABD, Elazig, Turkey

来源：

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY | 2019年 / 20卷 / 05期

关键词：

major depressive disorder; extended-release trazodone (single dose of TzCOAD per day); immediate-release trazodone (three doses of TzIR per day); PROLONGED-RELEASE; TOLERABILITY; EFFICACY;

D O I：

10.5455/apd.302644467

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.

引用

页码：453 / 459

页数：7

共 50 条

[1] Gepirone extended-release: New evidence for efficacy in the treatment of major depressive disorder
Feiger, AD
Heiser, JF
Shrivastava, RK
Weiss, KJ
Smith, WT
Sitsen, JMA
Gibertini, M
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (03) : 243 - 249
[2] Update on Pharmacological Treatment for Comorbid Major Depressive and Alcohol Use Disorders: The Role of Extended-release Trazodone
Di Nicola, Marco
Pepe, Maria
Panaccione, Isabella
Moccia, Lorenzo
Janiri, Luigi
Sani, Gabriele
CURRENT NEUROPHARMACOLOGY, 2023, 21 (11) : 2195 - 2205
[3] Gepirone extended-release (ER): New evidence for efficacy in the treatment of major depressive disorder
Gibertini, M
Feiger, AD
Heiser, JF
Shrivastava, RK
Weiss, KJ
Smith, WT
Sitsen, A
BIOLOGICAL PSYCHIATRY, 2002, 51 (08) : 41S - 41S
[4] Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
Huang, Qunlian
Zhong, Xiaoyan
Yun, Ye
Yu, Bin
Huang, Yilan
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 2707 - 2714
[5] Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy
Weisler, Richard
McIntyre, Roger S.
Bauer, Michael
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (11) : 1183 - 1200
[6] The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder
Weisler, Richard
McIntyre, Roger S.
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (11) : 1161 - 1182
[7] Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, JS
Aguiar, LM
Kunz, NR
Lei, D
JOURNAL OF PSYCHIATRIC RESEARCH, 2004, 38 (03) : 249 - 257
[8] Practical guidance for prescribing trazodone extended-release in major depression
Goracci, Arianna
Forgione, Rocco N.
De Giorgi, Riccardo
Coluccia, Anna
Cuomo, Alessandro
Fagiolini, Andrea
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 433 - 441
[9] Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Andrea Fagiolini
Alessandro Comandini
Mario Catena Dell’Osso
Siegfried Kasper
CNS Drugs, 2012, 26 : 1033 - 1049
[10] Rediscovering Trazodone for the Treatment of Major Depressive Disorder
Fagiolini, Andrea
Comandini, Alessandro
Dell'Osso, Mario Catena
Kasper, Siegfried
CNS DRUGS, 2012, 26 (12) : 1033 - 1049

← 1 2 3 4 5 →